Dimethylallyl Diphosphate

Identification

Generic Name
Dimethylallyl Diphosphate
DrugBank Accession Number
DB01785
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 246.0921
Monoisotopic: 246.005825762
Chemical Formula
C5H12O7P2
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UFarnesyl pyrophosphate synthaseNot AvailableHumans
UIsopentenyl-diphosphate Delta-isomerase 1Not AvailableHumans
U4-hydroxy-3-methylbut-2-enyl diphosphate reductaseNot AvailableEscherichia coli (strain K12)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Lovastatin Action PathwayDrug action
Cerivastatin Action PathwayDrug action
HypercholesterolemiaDisease
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)Disease
Smith-Lemli-Opitz Syndrome (SLOS)Disease
Mevalonic AciduriaDisease
Simvastatin Action PathwayDrug action
Pravastatin Action PathwayDrug action
Rosuvastatin Action PathwayDrug action
Zoledronate Action PathwayDrug action
Pamidronate Action PathwayDrug action
Fluvastatin Action PathwayDrug action
Lysosomal Acid Lipase Deficiency (Wolman Disease)Disease
Cholesteryl Ester Storage DiseaseDisease
Steroid BiosynthesisMetabolic
Ibandronate Action PathwayDrug action
Alendronate Action PathwayDrug action
Risedronate Action PathwayDrug action
Atorvastatin Action PathwayDrug action
DesmosterolosisDisease
CHILD SyndromeDisease
Hyper-IgD SyndromeDisease
Wolman DiseaseDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as isoprenoid phosphates. These are prenol lipids containing a phosphate group linked to an isoprene (2-methylbuta-1,3-diene) unit.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Isoprenoid phosphates
Direct Parent
Isoprenoid phosphates
Alternative Parents
Organic pyrophosphates / Monoalkyl phosphates / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aliphatic acyclic compound / Alkyl phosphate / Hydrocarbon derivative / Isoprenoid phosphate / Monoalkyl phosphate / Organic oxide / Organic oxygen compound / Organic phosphoric acid derivative / Organic pyrophosphate / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
prenol phosphate (CHEBI:16057) / C5 isoprenoids (hemiterpenes) (C00235) / C5 isoprenoids (hemiterpenes) (LMPR01010001)
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
358-72-5
InChI Key
CBIDRCWHNCKSTO-UHFFFAOYSA-N
InChI
InChI=1S/C5H12O7P2/c1-5(2)3-4-11-14(9,10)12-13(6,7)8/h3H,4H2,1-2H3,(H,9,10)(H2,6,7,8)
IUPAC Name
({hydroxy[(3-methylbut-2-en-1-yl)oxy]phosphoryl}oxy)phosphonic acid
SMILES
CC(C)=CCO[P@](O)(=O)OP(O)(O)=O

References

General References
Not Available
Human Metabolome Database
HMDB0001120
KEGG Compound
C00235
PubChem Compound
647
PubChem Substance
46507688
ChemSpider
627
ChEBI
16057
ChEMBL
CHEMBL343480
ZINC
ZINC000008215740
PDBe Ligand
DMA
PDB Entries
1uby / 1yhl / 2ick / 2zrx / 2zrz / 3b06 / 3epl / 3kef / 3oyr / 3q1o
show 18 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.54 mg/mLALOGPS
logP0.3ALOGPS
logP0.3Chemaxon
logS-1.6ALOGPS
pKa (Strongest Acidic)1.77Chemaxon
Physiological Charge-3Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area113.29 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity49.13 m3·mol-1Chemaxon
Polarizability19.19 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.6689
Blood Brain Barrier+0.8384
Caco-2 permeable-0.646
P-glycoprotein substrateNon-substrate0.5538
P-glycoprotein inhibitor INon-inhibitor0.8499
P-glycoprotein inhibitor IINon-inhibitor0.9464
Renal organic cation transporterNon-inhibitor0.9317
CYP450 2C9 substrateNon-substrate0.8176
CYP450 2D6 substrateNon-substrate0.838
CYP450 3A4 substrateNon-substrate0.5755
CYP450 1A2 substrateNon-inhibitor0.8712
CYP450 2C9 inhibitorNon-inhibitor0.8098
CYP450 2D6 inhibitorNon-inhibitor0.8769
CYP450 2C19 inhibitorNon-inhibitor0.791
CYP450 3A4 inhibitorNon-inhibitor0.9481
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9149
Ames testNon AMES toxic0.6544
CarcinogenicityCarcinogens 0.5
BiodegradationNot ready biodegradable0.6244
Rat acute toxicity2.7766 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9206
hERG inhibition (predictor II)Non-inhibitor0.9347
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-004j-9700000000-678abe159a77eee761ec
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0930000000-14b7c517a99324c3296b
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0290000000-67a537efa4078bbbc971
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kb-9000000000-eb6ac59562ea746e554d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-054k-9200000000-0672eda80afe285a6f0b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kb-9000000000-32c473865bd813e4a8b4
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-056r-9400000000-0e949f46aea92716edcc
1H NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-159.3251723
predicted
DarkChem Lite v0.1.0
[M-H]-159.7170723
predicted
DarkChem Lite v0.1.0
[M-H]-159.9804723
predicted
DarkChem Lite v0.1.0
[M-H]-129.38689
predicted
DeepCCS 1.0 (2019)
[M+H]+131.97932
predicted
DeepCCS 1.0 (2019)
[M+Na]+140.18771
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
FDPS
Uniprot ID
P14324
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Catalyzes the 1,3-allylic rearrangement of the homoallylic substrate isopentenyl (IPP) to its highly electrophilic allylic isomer, dimethylallyl diphosphate (DMAPP).
Gene Name
IDI1
Uniprot ID
Q13907
Uniprot Name
Isopentenyl-diphosphate Delta-isomerase 1
Molecular Weight
26318.93 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Converts 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate into isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). Is also involved in penicillin tolerance and control of the stringe...
Gene Name
ispH
Uniprot ID
P62623
Uniprot Name
4-hydroxy-3-methylbut-2-enyl diphosphate reductase
Molecular Weight
34774.275 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52